RetroSense Therapeutics Welcomes Dr. Steven Bramer as Chief Development Officer

<0> RetroSense TherapeuticsSharon Garcia, 312.933.7763 </0>

RetroSense Therapeutics, a biotechnology company dedicated to developing gene therapy approaches to vision restoration welcomes Steven Bramer, PhD to its senior management team as Chief Development Officer.

“Dr. Bramer brings a host of high-value skills to the team in drug development, business development, and beyond. As an all-around-athlete having great drug development experience, with an emphasis on ocular therapeutics, he is an outstanding complement to our executive team,” stated Sean Ainsworth, CEO and founder of RetroSense Therapeutics.

Dr. Steven Bramer has over 26 years of drug development experience. He has held positions in global companies where he contributed substantially to all stages of development for drugs, biologics, tissues, combination products, and devices. His experience covers a broad range of therapeutic areas, including ophthalmology, and he has dealt extensively with regulatory agencies in the US and abroad. Dr. Bramer has served in leadership roles throughout most of his career, leading departments, teams, and initiatives successfully – including his role as the Chief Drug Development Officer at the Foundation Fighting Blindness.

“I had the privilege of being introduced to the team at RetroSense while was the Chief Drug Development Officer at the Foundation Fighting Blindness. Of the numerous projects I had the pleasure of evaluating in that role, RetroSense’s optogenetic therapy stood out as an excellent opportunity to restore vision. What is unique and promising about this approach is the potential to restore vision in patients who have lost the function of their rods and cones due to a wide variety of causes. I am excited to work with RetroSense to bring this technology to the clinic and ultimately to the patients whose lives have been impacted by vision loss.”

Dr. Bramer will play a pivotal role in bringing RetroSense’s lead product, RST-001, into the clinic for the treatment of retinal degenerative conditions, such as retinitis pigmentosa and dry age-related macular degeneration.

Dr. Bramer holds an AS degree in Biology from Delhi College, BS degree in Animal Science from Cornell University, and has completed a MS program in Pathology and a Ph.D. in Pharmaceutics from The Ohio State University.

RetroSense Therapeutics is a biotechnology company developing a game-changing gene therapy to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved therapies to improve or restore vision in patients with these retinal degenerative conditions. RetroSense is led by a team of seasoned veterans with deep experience in taking products from the discovery stage through to the clinic. For more information about RetroSense, visit .

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.